NCT00520507View on ClinicalTrials.gov

An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Bipolar DisorderDepressionDepressive Disorder
Interventions
DRUG

Olanzapine

Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.

DRUG

Placebo

An inactive form of the treatment will be taken once daily at 6pm for 1 month.

Trial Locations (1)

K7L 4X3

Queen's University, Providence Care-Mental Health Services, Kingston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Queen's University

OTHER

NCT00520507 - An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients | Biotech Hunter | Biotech Hunter